Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine maintenance of effect study in disruptive behavioral symptoms in pediatric pervasive developmental disorders
2006-005346-37Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Irritability Subscale of the Aberrant Behavior Checklist.
02
Drugs
olanzapine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2006-005346-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005346-37.